Beijing Beilu Pharmaceutical Tangible Net Worth Ratio
Beijing Beilu Pharmaceutical tangible net worth ratio. Beijing Beilu Pharmaceutical (300016) has a Tangible Net Worth Ratio of 93.6% as of September 2025. This metric is calculated by deducting intangible assets (CN¥152.07 Million) from net assets (CN¥2.37 Billion) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore how fast is Beijing Beilu Pharmaceutical growing its equity to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Beijing Beilu Pharmaceutical (2005–2024)
Tangible net worth ratio of Beijing Beilu Pharmaceutical from 2005 to 2024. This chart shows how Beijing Beilu Pharmaceutical's Tangible Net Worth Ratio has changed across 20 annual periods from 2005 to 2024. As of September 2025, the ratio stands at 93.6%, reflecting net assets of CN¥2.37 Billion with intangible assets of CN¥152.07 Million CNY. Check Beijing Beilu Pharmaceutical strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Beijing Beilu Pharmaceutical Tangible Net Worth Ratio by Year (2005–2024)
Beijing Beilu Pharmaceutical tangible net worth ratio by year from 2005 to 2024. The table below presents the year-by-year Tangible Net Worth Ratio for Beijing Beilu Pharmaceutical from 2005 to 2024, covering 20 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see 300016 market cap overview.
| Year | Tangible NW Ratio | Net Assets (CNY) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 91.2% | CN¥1.83 Billion | CN¥160.82 Million | CN¥2.98 Billion | ▼ -1.6 pp |
| 2023 | 92.8% | CN¥1.79 Billion | CN¥128.39 Million | CN¥2.82 Billion | ▲ +0.5 pp |
| 2022 | 92.3% | CN¥1.92 Billion | CN¥147.26 Million | CN¥2.82 Billion | ▲ +0.0 pp |
| 2021 | 92.3% | CN¥2.08 Billion | CN¥160.39 Million | CN¥2.90 Billion | ▲ +1.1 pp |
| 2020 | 91.2% | CN¥1.89 Billion | CN¥167.07 Million | CN¥2.85 Billion | ▼ -4.9 pp |
| 2019 | 96.0% | CN¥1.45 Billion | CN¥57.71 Million | CN¥1.62 Billion | ▲ +0.1 pp |
| 2018 | 95.9% | CN¥1.21 Billion | CN¥49.69 Million | CN¥1.29 Billion | ▲ +0.9 pp |
| 2017 | 95.0% | CN¥1.07 Billion | CN¥53.26 Million | CN¥1.14 Billion | ▼ -0.2 pp |
| 2016 | 95.2% | CN¥901.69 Million | CN¥43.47 Million | CN¥956.09 Million | ▲ +0.7 pp |
| 2015 | 94.4% | CN¥932.63 Million | CN¥51.83 Million | CN¥1.05 Billion | ▲ +0.8 pp |
| 2014 | 93.7% | CN¥666.33 Million | CN¥42.07 Million | CN¥907.00 Million | ▼ -3.4 pp |
| 2013 | 97.1% | CN¥559.38 Million | CN¥16.05 Million | CN¥620.54 Million | ▼ -0.8 pp |
| 2012 | 98.0% | CN¥523.96 Million | CN¥10.70 Million | CN¥583.60 Million | ▼ -1.1 pp |
| 2011 | 99.1% | CN¥491.47 Million | CN¥4.54 Million | CN¥524.66 Million | ▲ +0.1 pp |
| 2010 | 99.0% | CN¥467.62 Million | CN¥4.60 Million | CN¥475.11 Million | ▼ -0.1 pp |
| 2009 | 99.1% | CN¥433.71 Million | CN¥3.90 Million | CN¥451.31 Million | ▲ +2.4 pp |
| 2008 | 96.7% | CN¥133.23 Million | CN¥4.40 Million | CN¥159.75 Million | ▲ +2.6 pp |
| 2007 | 94.0% | CN¥90.33 Million | CN¥5.38 Million | CN¥141.69 Million | ▼ -0.4 pp |
| 2006 | 94.5% | CN¥71.59 Million | CN¥3.95 Million | CN¥125.69 Million | ▲ +1.8 pp |
| 2005 | 92.7% | CN¥64.71 Million | CN¥4.72 Million | CN¥107.46 Million | — |